Common and Specific Effects of Selank, Noopept, and Semax to Glycine Site of the NMDA Receptor in BALB/c and C57Bl/6 Mice Brain

E. V. Vasileva; Васильева Е. В.; A. A. Abdullina; Абдуллина А. А.; G. I. Kovalev; Ковалёв Г. И.

doi:10.31857/S1027813323020176

Common and Specific Effects of Selank, Noopept, and Semax to Glycine Site of the NMDA Receptor in BALB/c and C57Bl/6 Mice Brain

Autores: Vasileva E.V.¹, Abdullina A.A.¹, Kovalev G.I.¹
Afiliações:
1. Zakusov Research Institute of Pharmacology
Edição: Volume 40, Nº 2 (2023)
Páginas: 157-165
Seção: Experimental Articles
URL: https://bakhtiniada.ru/1027-8133/article/view/142205
DOI: https://doi.org/10.31857/S1027813323020176
EDN: https://elibrary.ru/UDCZGN
ID: 142205

Citar

Texto integral

Acesso aberto
Acesso é fechado

Acesso está concedido
Acesso é fechado

Somente assinantes

Resumo
Sobre autores
Bibliografia
Arquivos suplementares
Estatísticas

Resumo

The effects of the nootropic peptides selank (300 mg/kg), noopept (1 mg/kg), and semax (0.6 mg/kg) after subchronic intraperitoneal (i.p.) and intranasal (i.n.) administration on the binding of [3H]-MDL105,51 to NMDA glycine site in BALB/c and C57Bl/6 mice brain were examined. It was found that in C57Bl/6 mice in comparison with BALB/c the number of glycine binding sites (B_max) at baseline was 15% higher in the cortex and 47% lower in the hippocampus. In the cortex i.n. administration of selank, noopept, and semax resulted in 18, 19, and 66% decrease in the number of glycine binding sites in BALB/c mice, and in 53, 49, and 66% in C57Bl/6 mice, respectively. In the hippocampus i.n. administration of selank, noopept, and semax resulted in 15, 63, and 95% increase in the number of glycine binding sites in BALB/c mice, respectively, while in C57Bl/6 mice all three peptides were not effective. In the cortex i.p. administration of selank and semax decreased glycine binding sites by 24 and 40% in the cortex and by 11 and 19% in the hippocampus in BALB/c mice, while in C57Bl/6 mice the reduction was 15% and 47% in the cortex and 45 and 24% in the hippocampus, respectively. Noopept did not affect the binding. These patterns observed in the cortex after i.n. and i.p. administration appear to be common to the both mice strains suggesting an engagement of the cortical NMDA glycine site in action(s) that underlie some common pharmacological effects of the selected peptides. Whereas the specific effect of selank, noopept, and semax after i.n. administration in the BALB/c hippocampi may be associated with the mechanisms of nootropic and anxiolytic activities of these peptides manifested in that mice strain.

Palavras-chave

selank, noopept, semax, mice, BALB/c, C57Bl/6, prefrontal cortex, hippocampus, NMDA-receptor, glycine site, [³H]-MDL105,519

Bibliografia

Телешова Е.С., Бочкарев В.К., Сюняков Т.С., Бугаева Т.П., Незнамов Г.Г. // Психиатрия. 2010. № 4. С. 26–35.
Ashmarin I.P., Nezavibatko V.N., Myasoedov N.F., Kamensky A.A., Grivennikov I.A., Ponomareva-Stepnaya M.A., Andreeva L.A., Kaplan A.Y., Koshelev V.B., Ryasina T.V. // Zh. Vyssh. Nerv. Deiat. 1997. V. 47. № 7. P. 429–430.
Gudasheva T.A, Voronina T.A., Ostrovskaya R.U., Rozantsev G.G., Vasilevich N.I., Trofimov S.S., Kravchenko E.V., Skoldinov A.P., Seredenin S.B. // Eur. J. Med. Chem. 1996. V. 31. P. 151–157.
Ковалев Г.И., Фирстова Ю.Ю., Салимов Р.М., Кондрахин Е.А. // Психиатрия. 2010. Т. 45. № 3. 23–27.
Васильева Е.В., Салимов Р.М., Ковалёв Г.И. // Экспериментальная и клиническая фармакология. 2012. Т. 75. № 7. С. 32–37.
Vasileva E.V., Kondrakhin E.A., Abdullina A.A., Salimov R.M., Kovalev G.I. // Neurochem. J. 2020. V. 14. № 3. P. 268–278.
Ковалёв Г.И., Кондрахин Е.А., Салимов Р.М., Незнамов Г.Г. // Экспериментальная и клиническая фармакология. 2013. Т. 76. № 9. С. 3–10.
Ковалёв Г.И., Кондрахин Е.А., Салимов Р.М., Незнамов Г.Г. // Экспериментальная и клиническая фармакология. 2014. Т. 77. № 12. С. 49–55.
Dauvermann M.R., Lee G., Dawson N. // Br. J. Pharmacol. 2017. V. 174. № 19. P. 3136–3160.
Haefely W., Kulcsár A., Möhler H. // Psychopharmacol. Bull. 1975. V. 11. P. 58–59.
Smith K.S., Engin E., Meloni E.G., Rudolph U. // Neuropharmacology. 2012. T. 63. P. 250–258.
Васильева Е.В., Кондрахин Е.А., Салимов Р.М., Ковалёв Г.И. // Экспериментальная и клиническая фармакология. 2016. Т. 79. № 9. С. 3–11.
Vasil’eva E.V., Abdullina A.A., Kovalev G.I. // Neurochem. J. 2021. V. 15. № 3. P. 260–265.
Traynelis S.F., Wollmuth L.P., McBain C.J., Menniti F.S., Vance K.M., Ogden K.K., Hansen K.B., Yuan H., Myers S.J., Dingledine R. // Pharmacol. Rev. 2010. V. 62. P. 405–496.
Stroebel D., Mony L., Paoletti P. // Neuropharmacology. 2021. V. 193. P. 1–12.
Finlay J.M., Dunham G.A., Isherwood A.M. // Brain Res. 2015. V. 1600. P. 70–83.
Grova N., Schroeder H., Farinelle S., Prodhomme E., Valley A., Claude P. Muller C.P. // Chemosphere. 2008. V. 73. P. S295–S302.
Glowinski L.L., Iversen J. // J. Neurochem. 1966. V. 13. № 8. P. 655–669.
Васильева Е.В., Салимов Р.М., Ковалёв Г.И. // Фармакокинетика и фармакодинамика. 2016. № 2. С. 31–36.
Parsons C.G., Danysz W., Quack G., Hartmann S., Lorenz B., Wollenburg C., Baran L., Przegalinski E., Kostowski W., Krzascik P., Chizh B., Headley P.M. // Journal of Pharmacology and Experimental Therapeutics. 1997. V. 283. № 3. P. 1264–1275.
Hanson L.R., Frey H.F. // BMC Neuroscience. 2008. № 9. P. S3–S5.
Illum L. // Eur. J. Pharm. Sci. 2000. № 11. P. 1–18.
Бойко С.С., Жердев В.П., Дворянинов А.А., Гудашева Т.А., Островская Р.У., Воронина Т.А., Розанцев Г.Г., Середенин С.Б. // Экспериментальная и клиническая фармакология. 1997. № 60. С. 101–104.
Potaman V.N., Antonova L.V., Dubynin V.A., Zaitzev D.A., Kamensky A.A., Myasoedov N.F., Nezavibatko V.N. // Neurosci. Lett. 1991. V. 127. № 1. P. 133–136.
Манченко Д.М., Глазова Н.Ю., Левицкая Н.Г., Андреева Л.А., Каменский А.А., Мясоедов Н.Ф. // Российский физиологический журнал им. И.М. Сеченова. 2010. Т. 96. № 10. С. 1014–1023.
Chen X.Q., Fawcett J.R., Rahman Y.E., Ala T.A. and Frey W.H. 2nd // J. Alzheimers Dis. 1998. V. 1. № 1. P. 35–44.
Фирстова Ю.Ю., Васильева Е.В., Ковалев Г.И. // Экспериментальная и клиническая фармакология. 2010. Т. 74. № 1. С. 6–10.
Mayer M.L., Vyklicky L., Clements J. // Nature. 1989. V. 338. P. 425–427.
Lerma J., Zukin R.S., Bennett M.V. // Proc. Natl. Acad. Sci. U. S. A. 1990. V. 87. P. 2354–2358.
Vyklický L., Benveniste M., Mayer M.L. // J. Physiol. 1990. V. 428. P. 313–331.
Awobuluyi M., Yang J., Ye Y., Chatterton J.E., Godzik A., Lipton S.A., Zhang D. // Mol. Pharmacol. 2007. V. 71. P. 112–122.
Grand T., Abi Gerges S., David M., Diana M.A., Paoletti P. // Nat. Commun. 2018. V. 9. № 4769.
Madry C., Mesic I., Bartholomaus I., Nicke A., Betz H., Laube B. // Biochem. Biophys. Res. Commun. 2007. V. 354. P. 102–108.
Skrenkova K., Hemelikova K., Kolcheva M., Kortus S., Kaniakova M., Krausova B., Horak M. // Sci. Rep. 2019. V. 9. № 12303.